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Abstract
Background
A quarter of the world’s population is estimated to be infected with Myobacterium tuberculo-
sis (Mtb). Infection is detected by immune response to M. tuberculosis antigens using either
tuberculin skin test (TST) and interferon gamma release (IGRA’s), tests which have low sen-
sitivity in immunocompromised. IL-7 is an important cytokine for T-cell function with potential
to augment cytokine release in in-vitro assays. This study aimed to determine whether the
addition of IL-7 in interferon-gamma release assays (IGRAs) improves its diagnostic perfor-
mance of Mtb infection.
Methods
44 cases with confirmed TB and 45 household contacts without TB were recruited and 1ml
of blood was stimulated in two separate IGRA’s tube set: one set of standard Quantiferon
TB gold tubes mitogen, TB antigen and TB Nil; one set of customized Quantiferon TB gold
tubes with added IL-7. Following IFN-γ and IP-10 release was determined using ELISA.
Results
We found that the addition of IL-7 led to significantly higher release of IFN-γ in individuals
with active TB from 4.2IU/ml (IQR 1.4–6.9IU/ml) to 5.1IU/ml (IQR 1.5–8.1IU/ml, p = 0.0057),
and we found an indication of a lower release of both IFN-γ and IP-10 in participants with
negative tests.
Conclusions
In TB cases addition of IL-7 in IGRA tubes augments IFN-γ but not IP-10 release, and
seems to lower the response in controls. Whether IL-7 boosted IGRA holds potential over
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Introduction
The need for improved diagnostics and ultimately a new vaccine for tuberculosis (TB) cannot
be overemphasized. An estimated quarter of the global population is infected with Mycobacte-
rium tuberculosis (Mtb) [1], and in 2015 alone, 10.4 million people developed TB and 1.8 mil-
lion people died of TB [2]. The new WHO end TB strategy aims to reduce new TB cases by
90% until 2035 through better use of available technology along with introduction of better
diagnostic tools and better vaccines [3]. The implementation plan behind these ambitious
goals introduced a shift from active case finding to a test-to-treat strategy of individuals
infected with Mtb at risk of developing TB.
A major roadblock in the test-to-treat strategy is the poor understanding of Mtb infection
and absence of strong correlates for development of active TB disease in those infected. Cur-
rent state-of-art consider Mtb infection as a dynamic condition wherein the outcome of the
infection (progression or control) is strongly dependent on the initial encounter between
immune system and bacterium and risk factors for progression e.g., HIV infection [4,5]. The
adaptive immune response plays a central role in the control of the infection especially through
induction of CD4+ T cells [6]. Several small and highly recognized antigens secreted by Mtb
are essential factors for the virulence of the bacterium [7]. These antigens includes ESAT-6
and its secretion partner CFP-10 and the fact that these antigens are recognized by the majority
of infected individuals has enabled the development of the interferon gamma release assays
(IGRA), an in-vitro diagnostic concept for specific detection of infection [8,9]. In IGRAs,
immune competent cells either in the form of whole blood (as in the Quantiferon Gold In-
Tube (QFT)) or purified peripheral mononuclear cells (PBMCs, as in the T-SPOT.TB test) are
stimulated in-vitro with ESAT-6 and CFP-10 and the degree of immune recognition is deter-
mined by measurement of the antigen specific release of interferon-gamma (IFN-γ) [9]. A
major limitation to the use of IGRAs is that the tests rely on live cells to generate the result.
This require a robust laboratory and sample handling framework as well as technical expertise
for efficient sample handling and analysis, which can be a challenge in most settings wherein
the test-to-treat strategy is intended to be implemented [9]. Another challenge with the IGRAs
is their poor predictive value for development of active TB [10] and IGRAs can be false nega-
tive in high risk groups e.g., HIV infected [9].
Attempts to improve the robustness of the IGRA technology have been ongoing for a
decade, and it is now recognized that IFN-γ is only one of several markers with immunodiag-
nostic potential, among whom IP-10 is a leading alternative expressed in 100 fold higher levels
[11]. Attempts to stabilize and prolong the responsiveness of the immune competent cells in
the IGRA includes blockade of anti-inflammatory cytokines (e.g. IL-10) [12], elimination of
granulocytes during cell preparation for the T-SPOT.TB [13], as well as addition of immune
mediators which role it is to improve survival of T cells [14]. IL-7 is a key regulator of CD4+ T
cells survival, both long term and cells responding to antigen. Previous studies have shown
that IL-7 increases both frequency and spot size in the T-SPOT.TB assay improving overall
diagnostic performance of the IGRA [12,15,16]. The aim of this study was to develop a ready-
to-use vacutainer tube system comprising IL-7 and the QFT Ag cocktail, and to assess its per-
formance in terms of magnitude of cytokine release and diagnostic performance.
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Material and methods
Study setting, study population, and procedures
The study was conducted within the frame of an ongoing prospective cohort from November
2014 to April 2016 study of adult (18 years) TB patients and household contact (controls) in
the Temeke district, Dar es Salaam, Tanzania (TB-DAR) [17] Cases were defined as TB
patients with a positive sputum smear result for acid-fast bacilli [AFB] and a positive TB cul-
ture on solid media. Household contact controls were exposed to a TB case in the household,
but with a negative sputum smear microscopy and Xpert MTB/RIF results, matched to the
case by age (±5 years) and whenever possible by sex. We did not include a control group with
individuals unlikely to have latent tuberculous infection (LTBI) because the study setting was
in the high TB endemic area.
Study participants were routinely screened for malaria, helminth infections (Kato-Katz,
Baermann, urine filtration) at the time of enrolment. We recruited 50 cases and 50 controls for
this study. After exclusion of study participants with missing samples or not enough sample
volume (<1ml), we finally included 44 cases and 45 controls.
IL-7 Tube preparation. Under sterile conditions, caps were removed from QFT nil and
antigen tube (Qiagen, DE) and recombinant IL-7 (Thermo Fisher Scientific, Waltham, MA,
USA) diluted in sterile water to a final concentration of 1μg/ml was added in a 2μl droplet to
the side of the tube[18]. Tubes were covered with sterile tin foil, frozen at -80˚C for 24h before
freeze drying. Following, tubes were recapped and kept in plastic zipper bags with desiccant
and stored for 4˚C until use. On day of use, vacuum sufficient for 1ml blood draw was created
using a syringe and needle as described elsewhere (19).
Interferon-gamma release and IP-10 release testing. Whole blood was drawn into vacutai-
ner tubes and within 4 hours placed in a 37˚C incubator for 18 24 hours. Here after plasma was
isolated by centrifugation and samples were stored at -20˚C for later analysis. IFN-γ levels were
detected using sandwich ELISA as per manufacturers’ instructions (Qiagen, Germany) and IP-10
was measured in plasma diluted x30 using a qualified in-house ELISA described previously (20)
Statistical analysis. The antigen specific release of IFN-γ and IP-10 was determined after
subtraction of the unstimulated (nil) sample from the antigen sample. IFN-γ and IP-10 release
was compared between groups using non-parametric test (Kruskal-Wallis test). Diagnostic
potential independent of cut off was assessed by comparing cases and controls using Receiver
Operations Characteristics Curve analysis (ROC). After application of cut off (0.35IU/ml) the
diagnostic potential was assessed using McNemars test. Analyses were performed in SAS 9.2
and GraphPad Prizm 7.02.
Ethics statement
The study protocol was approved by the institutional review board of the Ifakara Health Institute
(IHI; reference no. IHI/IRB/No 04–2015) and the Medical Research Coordinating Committee of
the National Institute of Medical Research (NIMR; reference no. NIMR/HQ/R.8c/Vol.I/357) in
Tanzania, and the ethics committee of north-west and central Switzerland (EKNZ; reference no:
UBE-15/42). Written informed consent was obtained from all study participants.
Results
Study population
We analyzed 44 TB cases and 45 household controls without TB. TB cases were more likely
male (68.1% vs. 28.9%), had a lower median body mass index (BMI) at the time of TB diagno-
sis (17.6 vs. 25.2 kg/m2), and were more likely to be HIV-positive (27.3% vs. 4.4%) compared
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to controls, whereas distributions of age, sex, smoking, and intestinal infection were similar.
Among household contacts, 48.9% had positive QFT status shown and one test indeterminate
(Table 1).
Table 1. Patient characteristics of tuberculosis cases and household contact controls without TB, Dar es Salaam, Tanzania.
Characteristic All Cases Controls
Total, n (%) 89 (100) 44 (49.4) 45 (50.6)
Age, years, median (IQR) 32 (25.6–42.0) 33.92 (28–43.3) 30.44 (23.4–38.6)
Female sex, n (%) 50 (56.2) 18 (40.9) 32 (71.1)
BMI, kg/m2, median (IQR) 21.05 (17.8–25.24) 17.58 (15.98–20.4) 25.22 (21.98–32.1)
Current smoker, n (%) 12 (13.48) 6 (13.64) 4 (13.33)
Occupation, n (%)
Unemployed 32 (36.0) 11 (25.0) 21 (46.7)
Employed 57 (64.0) 33 (75.0) 24 (53.3)
Monthly income (USD), n (%)
<100 42 (47.2) 23 (52.3) 19 (42.2)
100 47 (52.8) 21 (47.7) 26 (57.8)
Education level, n (%)
No/primary 77 (86.5) 39 (88.6) 38 (84.4)
Secondary/University 12 (13.5) 5 (11.4) 7 (15.6)
Symptoms 1, n (%)
Coughing 64 (71.9) 42 (95.5) 22 (48.9)
Fever 43 (48.3) 32 (72.7) 11 (24.4)
Night sweats 54 (60.7) 37 (84.1) 17 (37.8)
Unexplained weight loss 47 (52.8) 42 (95.5) 5 (11.1)
HIV infection, n (%) 14 (15.7) 12 (27.3) 2 (4.4)
CD4+ count (cells/μl), median (IQR)2 140 (87.5–170) -
Full blood counts 1 (109 cells/L)
Neutrophils, median (IQR) 4.1 (2.8–5.7) 5.0 (3.8–6.4) 2.7 (2.1–3.3)
Platelets, median (IQR) 278.5 (207.0–376.5) 350 (247.0–420.0) 244.0 (196.0–299.0)
Red blood cells, mean (±SD) 4.75 (0.8) 4.54 (0.8) 4.9 (0.7)
Hemoglobin (g/dL) 1, mean (±SD) 11.88 (2.2) 11.27 (2.4) 12.44 (1.8)
Any helminth infection 1, n (%) 20 (22.5) 11 (25.0) 9 (20.0)
TB patient category
New case 43 (97.7) 43 (97.7) -
Relapse 1 (2.3) 1 (2.3) -
AFB smear microscopy result, n (%)
Scanty 2 (4.55) 2 (4.55) -
1+ 13 (29.6) 13 (29.6) -
2+ 20 (45.5) 20 (45.5) -
3+ 9 (20.5) 9 (20.5) -
QFT Status
Positive 60 (68.2) 38 (86.4) 22(48.9)
Negative 28 (31.8) 6(13.6) 22(48.9)
Indeterminate - - 1(2.2)
AFB, Acid fast bacilli; BMI, body mass index; IQR, Interquartile range; SD, Standard deviation; TB, Tuberculosis; USD, United States Dollar
1 at the time of TB diagnosis (cases) or enrolment
2CD4+ cell counts were only available among HIV positive TB cases (all were naïve to antiretroviral therapy)
https://doi.org/10.1371/journal.pone.0202525.t001
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Impact of IL-7 on IFN-γ and IP-10 release in cases and controls
The antigen specific release of IFN-γ was higher in TB patients median 4.2IU/ml (IQR 1.4–
6.9IU/ml) compared to controls median 0.5IU/ml (IQR 0.0–3.9IU/ml, p<0.0001) (Fig 1).
Adding IL-7 led to a more categorical separation between cases and controls, through a signifi-
cantly higher antigen specific release in cases from median 4.2IU/ml (IQR 1.4–6.9IU/ml) to
5.1IU/ml (IQR 1.5–8.1IU/ml, p = 0.0057) and an overall albeit not significantly lower release
in controls from median 0.5IU/ml (IQR 0.0–3.9IU/ml) to 0.2IU/ml (IQR 0.0–4.7). Interest-
ingly, IFN-γ levels in the nil tube were unaffected by the presence of IL-7 (p = 0.501, data not
shown).
Antigen specific release of IP-10 was significantly higher in cases compared to controls,
median (4.9ng/ml (IQR 1.3–6.9ng/ml) vs 0.3ng/ml (IQR 0.0–2.6ng/ml, p<0.0001) (Fig 1). Of
note, we did not find a significantly higher IP-10 release with IL-7 in stimulated samples from
cases as seen with IFN-γ (Fig 1B), but IL-7 did seem to drive a similar non-significant contrac-
tion in the IP-10 release in controls as seen for IFN-γ (0.3ng/ml (IQR 0.0–2.6ng/ml) to 0.1ng/
ml (IQR 0.0–1.6ng/ml) (Fig 1).
The ROC curve analysis did not show a significant impact of added IL-7 on either IFN- γ or
IP-10 (area under the curve IFN- γ with IL-7 0.73 [95% CI 0-63-0.84], IFN-γ without IL-7:
0.71 [95% CI 0.60–0.82] and IP-10: 0.76 (95% CI 0.66–0.86, data not shown). However, by
plotting sensitivity and specificity with or without IL-7 against potential cut offs, it was illus-
trated how the contracted IFN-γ response and herewith lower variability seen in the IL-7
treated control samples, has potential for improved diagnostic sensitivity in tests with cut offs
<0.8IU/ml (Fig 2).
Diagnostic performance of IL-7 coated tubes
Splitting study participants by QFT status demonstrated that the presence of IL-7 did not lead
to significant differences in the magnitude of IFN-γ or IP-10 release within the groups (Fig 3).
After applying the manufacturers recommended cut off of 0.35IU/ml for IFN-γ and 0.75 ng/
ml IP-10 tests, there were no significant change the number of positive results in either cases
(n = 38 (86%) and n = 39 (88%)) or household contacts controls (n = 22 (49%) and n = 20
(44%), S1 Table). IP-10 had comparable diagnostic performance with QFT in cases; n = 37
(84%) and controls; n = 18 (40%) (S2 Table).
Fig 1. A comparison of the effect of added IL-7 on antigen specific release of IFN-γ (A) and IP-10 (B) in TB cases
(n = 44) and endemic controls (n = 45). Whole blood was incubated 18–24 hours whereupon plasma was isolated for
later analysis with ELISA.
https://doi.org/10.1371/journal.pone.0202525.g001
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Discordant results
Addition of IL-7 resulted in discordance in 7/44 (16%) cases and 10/45 (22%) controls in the
IFN-γ based tests (Table 2). Two reversions (one case and one control) and two conversions
(one cases and one control) were caused by smaller differences in IFN-γ release (<0.50IU/ml),
changes more likely caused by analytical variability than an IL-7 effect [19]. However, the
remaining 13 participants had discordant results, which could not be explained by analytical
variability. Nine QFT positive revert to negative with added IL-7 during the stimulation. Five
were controls and except for one who reverted from 0.66IU/ml to 0.17IU/ml the remaining
five controls were “true reverters” with dramatic reduction in release >2.87IU/ml. Only one
was positive with IP-10 without IL-7 and all were IP-10 negative when IL-7 was added
(Table 2). These study participants with discordant responses tended to have a lower BMI, but
were all HIV-negative and otherwise comparable to the remaining cohort.
Discussion
In this study, we explored added value of IL-7 on whole blood stimulation in IFN-γ and IP-10
release assays. We found that IL-7 led to significantly higher release of IFN-γ in individuals
with active TB p = 0.0057 and we found an indication of a lower release of both IFN-γ and IP-
10 in controls. The impact of IL-7 on IFN-γ release was most pronounced in controls with a
positive QFT.
Fig 2. Comparison of added IL-7 for positive test on sensitivity and specificity in IFN-γ release assay. The dotted
line indicates the 0.35 IU/ml cut off recommended by the manufacturer.
https://doi.org/10.1371/journal.pone.0202525.g002
Fig 3. A comparison of the effect of added IL-7 on antigen specific release of IFN-γ (A) and IP-10 (B) in
Quantiferon (QFT) negative (n = 28) and QFT positive (n = 60). Whole blood was incubated 18–24 hours
whereupon plasma was isolated for later analysis with ELISA. Lines denote median, p-value calculated using Kruskal-
wallis test.
https://doi.org/10.1371/journal.pone.0202525.g003
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IL-7 is an essential cytokine for T cell development as well as for the survival and homeosta-
sis of mature T cells [20–22]. Disruption of the IL-7 axis leads to severe lymphopenia, and
administration of IL-7 in HIV seropositive people and patients suffering from other types of
lymphopenia, results in rapid replenishment of the T cell pool, promote T cell expansion and
normalization of lymphocyte functions [21,23]. These interesting effects of IL-7 are being
explored as adjunct therapy e.g., after bone marrow transplantation [21,24,25]. The IL-7 recep-
tor is almost exclusively expressed on lymphoid cells, and IL-7 receptor ligation activates sev-
eral pathways including Jak-Stat5 (to promote T cell differentiation), the PI3K/Akt pathway
(responsible for survival), as well as upregulation of several anti-apoptotic genes including Bcl-
2 and MCL1 [20,21,24].
The biological effects of IL-7 suggest it has benefits to promote cytokine release in cell medi-
ated immune response assays like the IGRA. When primed with specific antigens, IL-7 has an
effect on TCR activation in mature T cell through expansion of T cells specific to the antigens
[22] in concert with stabilized INF-γ signaling and augmented IL-2 receptor expression also
on terminally differentiated T cells [20,21,26].
These findings have been translated to the IGRA test concept, where IL-7 primed with Mtb
specific antigens has been shown to increase IFN-γ mRNA levels and increase IFN-γ protein
production (2–14 fold increase) [16,18,27] and promote larger spot size in the T-SPOT.TB
IGRA [15,28]. Our study is the first confirming the effects of higher Mtb antigen specific IFN-
γ release in a larger material and our use of a field friendly method of IL-7 prepared blood col-
lection tubes opens for further larger studies (Fig 2). Our findings also expands previous
knowledge by demonstrating a more categorical separation between TB cases and controls
potentially due to stabilization of IFN-γ translation as reported in previous studies [18,27,28].
In agreement with other reports, addition of IL-7 did not augment the antigen specific IP-
10 release in cases, but it had an effect by stabilizing the unspecific release in nil samples and in
the controls [18]. This absence of augmented release is a somewhat surprising finding as IP-10
Table 2. Test results, IFN-γ and IP-10 release levels in participants with discordant outcome of IFN-γ based test.
Status QFT
result
QFT+IL-7 result IP-10 result IFN-γ (Ag-Nil) IFN-γ+IL7 (Ag-Nil) IP-10 (Ag-Nil) Dif. +/- IL-7
Conversion Case NEGATIVE POSITIVE NEGATIVE 0.04 6.9 -0.01 6.86
Case NEGATIVE POSITIVE NEGATIVE 0.28 0.58 0.13 0.30
Case NEGATIVE POSITIVE NEGATIVE 0.06 1.53 -0.05 1.47
Case NEGATIVE POSITIVE POSITIVE 0.15 2.62 1.04 2.47
Control NEGATIVE POSITIVE NEGATIVE -0.01 3.54 0.07 3.55
Control NEGATIVE POSITIVE NEGATIVE -1.72 0.38 0.03 2.10
Control NEGATIVE POSITIVE NEGATIVE 0.76 6.14 0.35 5.38
Control NEGATIVE POSITIVE NEGATIVE 0.33 0.42 0.68 0.09
Reversion Case POSITIVE NEGATIVE NEGATIVE 0.74 -0.08 0.51 -0.82
Case POSITIVE NEGATIVE POSITIVE 0.77 0.34 2.89 -0.43
Case POSITIVE NEGATIVE POSITIVE 4.64 0.22 3.75 -4.42
Control POSITIVE NEGATIVE POSITIVE 5.54 0.05 7.05 -5.49
Control POSITIVE NEGATIVE POSITIVE 3.32 0.03 8.15 -3.29
Control POSITIVE NEGATIVE NEGATIVE 0.66 0.17 -0.12 -0.49
Control POSITIVE NEGATIVE NEGATIVE 2.87 -0.01 0.01 -2.88
Control POSITIVE NEGATIVE NEGATIVE 7.53 -0.06 -0.07 -7.59
Control POSITIVE NEGATIVE NEGATIVE 6.08 -0.12 0.33 -6.20
 denotes participants with a difference in IFN-γ release between IL-7 boosted and standard QFT within the range of expected analytical variability of the assay.
https://doi.org/10.1371/journal.pone.0202525.t002
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release by the antigen presenting cell (APC) is augmented by IFN-γ, TNF and other cytokines
released by the specific T cell recognizing its antigen on the APC [11]. A likely explanation to this
apparent paradox could be that the IL-7 mediated effects on IFN-γ release occur at a late stage of
the relatively short 18–24 hour stimulation assay, whereas the co-stimulatory effects of IFN-γ on
STAT1 activation and IP-10 release is more effective if it occurs early during the incubation [11].
Kinetic studies are required to elucidate the interplay of these potential effects, however the IL-7
effect of lower variability in IP-10 release among controls, supports this hypothesis.
One of the limitations in the IGRAs especially in the high endemic setting, is the frequent
occurrence of low level responses in the ‘uncertainty zone’ between 0.2–0.7IU/ml, responses with
high likelihood of conversion and reversion with serial testing [19,29,30]. QFT positives with IFN-
γ release falling within the ‘uncertainty zone’ (0.35 to 0.7IU/ml) are particularly likely to revert,
and it was very recently shown that these individuals had the same low risk of progression to TB
as the QFT negatives[30]. Moreover, the group of strict converters (defined as a change from
<0.2 to>0.7IU/ml) comprised almost all individuals who later developed TB disease, suggesting
that interpretation of serial QFT tests taking the ‘uncertainty zone’ into account could improve
preventive treatment by only offering treatment to strict converters[30]. A major contributor to
low-level responses in the ‘uncertainty zone’ is the biological variability of IFN-γ release in this
rather complex in-vitro assay. Our findings suggest that some of the biological variability of the
QFT can be curbed by IL-7 mediated stabilization of the IFN-γ response, allowing for a clearer
separation between cases and endemic controls [18,27,28]. Further studies are needed to assess
whether IL-7 has a potential to improve management of preventive treatment.
Although our exploratory study was insufficiently powered to demonstrate a significance in
diagnostic sensitivity, it suggested that in the presence of IL-7 there was also a tendency for
reversion of positives to negative in controls. Overall the IGRA positive population have an
increased risk of developing TB, however studies suggest this risk is relatively low[31], further
studies are required to determine if the observed discordance with added IL-7 leads to a more
accurate risk stratification.
Limitation to be taken into account was missing data for the few patients which were taken
out of analysis reducing the sample size. The small size of this study limits the generalizability
of the findings but is acceptable for proof of concept assessment of novel concepts like freeze-
drying IL-7 in the QFT tubes. The use of endemic controls in exploratory studies is another
limitation preventing true assessment of the specificity of the IL-7 concept, however with no
indication of altered specificity through increased unspecific IFN-γ secretion in this report and
in the literature, warrants our approach[15,18,28].
In conclusion, we found that the addition of IL-7 in IGRA tubes has a positive effect on
IFN-γ expression, but not on IP-10 expression. This suggested a potential superior diagnostic
potential for IL-7 boosted IGRAs. Another potential clinical implication suggested by the data
is improved diagnostic sensitivity in high-risk groups. Prompted by the observed lower IFN-γ
release in the endemic control group suggests that the cut off can be lowered for an IL-7 aug-
mented IGRA to enable improved diagnostic sensitivity in children and immunosuppressed
individuals such as e.g., HIV infected. The diagnostic potential of IL-7 needs to be confirmed
in larger studies in high and low TB incidence countries, however our demonstration of a IL-7
coated ready to use antigen tube should make such evaluation feasible
Supporting information
S1 Table. Quantiferon vs., IL-7 boosted Quantiferon calculated with the standard 0.35 IU/
ml cut off.
(DOCX)
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S2 Table. Quantiferon vs., IP-10 determined in Quantiferon supernatant, IP-10 cut off at
0.75 ng/ml.
(DOCX)
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